Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP861576.RA1jx8RFruR56DaBSMqxnYhvEx8N134xXHa7AFdD6l3T0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP861576.RA1jx8RFruR56DaBSMqxnYhvEx8N134xXHa7AFdD6l3T0130_assertion type Assertion NP861576.RA1jx8RFruR56DaBSMqxnYhvEx8N134xXHa7AFdD6l3T0130_head.
- NP861576.RA1jx8RFruR56DaBSMqxnYhvEx8N134xXHa7AFdD6l3T0130_assertion description "[Thus, this study has confirmed that the BRAF(T1799A) mutation confers cancer cells sensitivity to PLX4032 and demonstrated its specific potential as an effective and BRAF(T1799A) mutation-selective therapeutic agent for thyroid cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP861576.RA1jx8RFruR56DaBSMqxnYhvEx8N134xXHa7AFdD6l3T0130_provenance.
- NP861576.RA1jx8RFruR56DaBSMqxnYhvEx8N134xXHa7AFdD6l3T0130_assertion evidence source_evidence_literature NP861576.RA1jx8RFruR56DaBSMqxnYhvEx8N134xXHa7AFdD6l3T0130_provenance.
- NP861576.RA1jx8RFruR56DaBSMqxnYhvEx8N134xXHa7AFdD6l3T0130_assertion SIO_000772 21185263 NP861576.RA1jx8RFruR56DaBSMqxnYhvEx8N134xXHa7AFdD6l3T0130_provenance.
- NP861576.RA1jx8RFruR56DaBSMqxnYhvEx8N134xXHa7AFdD6l3T0130_assertion wasDerivedFrom befree-2016 NP861576.RA1jx8RFruR56DaBSMqxnYhvEx8N134xXHa7AFdD6l3T0130_provenance.
- NP861576.RA1jx8RFruR56DaBSMqxnYhvEx8N134xXHa7AFdD6l3T0130_assertion wasGeneratedBy ECO_0000203 NP861576.RA1jx8RFruR56DaBSMqxnYhvEx8N134xXHa7AFdD6l3T0130_provenance.